Researchers have developed a drug that can break through the mucus barrier
A capsule that tunnels through mucus in the gastrointestinal tract could be used to orally administer large protein drugs such as insulin.
List view / Grid view
A capsule that tunnels through mucus in the gastrointestinal tract could be used to orally administer large protein drugs such as insulin.
Researchers have discovered a protein, Ait1, that is responsible for controlling cell growth in yeasts. Since humans and yeasts have remarkably similar cellular mechanisms, teasing out the differences presents drug developers with new target.
Researchers found that uniformly charged macromolecules — or molecules, such as proteins or DNA, which contain many atoms all with the same electrical charge — can self-assemble into very large structures.
Researchers in Japan have succeeded in inhibiting cancer cell growth using pyrrolizidine alkaloid, a component of plant origin previously thought to be too toxic to administer.
Helen Harrison, Director of Screening at Amphista Therapeutics, discusses targeted protein degradation (TPD) and the discovery of drugs in this area.
Discover all the ways you can harness ultrasensitive immunoassays to stay at the forefront of neuroscience research.
Europe’s largest meeting for life sciences professionals is just around the corner – be a part of it. This year, Drug Discovery 2022 is coming to the ever-buzzing ExCel centre in London from 4-5 October and will focus on ‘driving the next life sciences revolution’ as we build new momentum…
Compendium of iQue® advanced flow cytometry platform application posters: Antibody discovery and immuno-oncology.
A recently discovered SARS-CoV-2 virus in a Russian bat is likely to be capable of infecting humans and resistant to current vaccines.
Discover how picodroplet microfluidic technologies can identify and isolate 'hit' cells, quantify varying concentrations of antigen-specific antibodies and much more.
Alzheimer’s disease remains one of the largest challenges for the global ageing population. In this article, Victoria Rees, Editor of Drug Target Review, reviews some of the latest research, highlighting how progress has been made in understanding tau as well as how to potentially target this protein as a therapeutic strategy against…
Learn how R&D Systems™ Avi-tag biotinylated proteins can be used as an alternative to amine biotin coupling in surface plasmon resonance experiments.
After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.
Antibody therapy has been a critical part of the COVID-19 research campaign to treat severe cases. Unfortunately, despite many promising candidates, scientists have yet to find one that passes clinical trials. This article by Drug Target Review’s Ria Kakkad highlights some of the most recent developments in the search for COVID-19…
In this exclusive Q&A, Drug Target Review’s Ria Kakkad spoke with Dr Jonathan Javitch, Professor at Columbia University’s Vagelos College of Physicians and Surgeons, about the cutting-edge imaging method single-molecule fluorescence resonance energy transfer (smFRET), used to investigate G protein-coupled receptors (GPCRs).